- In March 2021, Kiniksa Pharmaceuticals, Ltd. announced that the United States Food and Drug Administration (FDA) approved ARCALYST (rilonacept), a recombinant fusion protein administered weekly via subcutaneous injection. The drug blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling, and is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children aged 12 years and older
- In May 2022, Cardiol Therapeutics revealed that it had received FDA Investigational New Drug (IND) authorization to initiate a multicenter Phase II open-label pilot study of CardiolRx for recurrent pericarditis
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Medication, Surgery, Fluid Draining, and Others), Diagnosis (Chest X-ray, Computerized Tomography (CT) Scan, Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), and Others), Symptoms (Anxiety, Feeling of Abdominal Fullness, Chest Pain, Confusion, Restlessness, Shortness of Breath, Cough, Fainting, Heart Palpitations, Light Headedness, Nausea, Swelling in the abdomen and legs, and Others), Dosage (Tablet, Injection, and Others), Route of Administration (Oral, Intravenous, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Pericardial Effusions Treatment Market size was valued at USD 371.02 USD Million in 2024.
The Global Pericardial Effusions Treatment Market is projected to grow at a CAGR of 6.84% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
